Leerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015November 5, 2015 8:00 AM Regeneron (REGN) Reports Strong Eylea Sales; Cowen Reiterates Market Perform November 4, 2015 3:55 PM Regeneron (REGN) Tops Q3 EPS by 33cNovember 4, 2015 6:31 AM Regeneron Reports Third Quarter 2015 Financial and Operating ResultsNovember 4, 2015 6:30 AM Trading Radar 11/4: Facebook (FB), Qualcomm (QCOM), MetLife (MET), Time Warner (TWX), Michael Kors (KORS) ReportNovember 3, 2015 2:45 PM